- Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
- Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
- Denali Therapeutics Announces $500 million Private Placement Equity Financing
- Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
- Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
- Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
- Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
- Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023
- Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
More ▼
Key statistics
As of last trade, Denali Therapeutics Inc (4DN:DUS) traded at 15.51, 12.92% above the 52 week low of 13.74 set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 15.66 |
---|---|
High | 15.66 |
Low | 15.51 |
Bid | 16.24 |
Offer | 16.36 |
Previous close | 15.47 |
Average volume | 109.89 |
---|---|
Shares outstanding | 142.54m |
Free float | 122.96m |
P/E (TTM) | -- |
Market cap | 2.40bn USD |
EPS (TTM) | -1.09 USD |
Data delayed at least 15 minutes, as of May 03 2024 11:31 BST.
More ▼